News and features

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.

A ‘TripAdvisor-style’ website that helps scientists choose the best small-molecule tools for their experiments has been greatly expanded to include expert reviews of hundreds of chemical probes that can be used to increase the robustness of fundamental and applied research and help develop an arsenal of new cancer drugs.

Sentinal4D, a spinout company from The Institute of Cancer Research, London, has been announced to the public – having closed of its first round of funding and appointed its foundational leadership team.

Christmas arrived in style as celebrities and guests got into the festive spirit at Carols from Chelsea – raising more than £125,000 for The Institute of Cancer Research, London

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.

We've selected a range of discoveries from 2023/24 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal Cancer Cell.

Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options for cancer patients.

Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, according to new research.

Researchers have identified a key weakness in acute myeloid leukaemia, offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting the function of a certain protein complex that cancer cells, including leukaemia cells, rely on to maintain their abnormal growth.